UP202-56 is an adenosinergic agonist and is an adenosine analog.

UP202-56(oral administration) are assessed on carrageenan-induced spinal c-Fos protein expression and peripheral oedema. Oral UP202-56 (10, 30 or 50 mg/kg) dose-dependently reduces the number of carrageenan-induced c-Fos like immunoreactivity (c-Fos-LI) neurons (r=0.931. P<0.0001), with the highest dose of UP202-56 producing 72±4% reduction of the total number of carrageenan-induced spinal c-Fos-LI neurons, and 12±3% and 33±6% of reduction of control carrageenan oedema at paw and ankle levels, respectively.UP202-56 dose-dependently reduced the expression of spinal cord c-Fos protein in carrageenan inflammatory pain model [1]. UP202-56 is an adenosine agonist[2].